Inflammatory Bowel Diseases publishes original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of IBD that will lead to advancements in overall clinical care. Submit your article …

Each issue contains original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of inflammatory bowel disease (IBD) that will lead to advancements in overall clinical care.

Inflammatory Bowel Diseases, Volume 31, Issue 1, January 2025, Pages 210–219, https://doi.org/10.1093/ibd/izae033 Abstract Lay summary

Inflammatory Bowel Diseases® (IBD) supports the mission of the Crohn's & Colitis Foundation by bringing the most impactful and cutting-edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics ...

Postpartum Wound Healing for Mothers with Inflammatory Bowel Disease: Cause for Worry? Insights from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Registry

Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 297–307, https://doi.org/10.1093/ibd/izac124 Abstract Lay summary

2022年4月4日 · Inflammatory Bowel Diseases® invites technical reviews or original research articles that add to the body of knowledge of the current status of in vivo, ex vivo, in silico, and humanized preclinical models of Crohn’s disease and ulcerative colitis.

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA ®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS

2024年5月23日 · To address the unmet medical needs of patients with inflammatory bowel diseases (IBD) and move toward cures, preclinical human-relevant research must center on mechanistic questions pertinent to patients with IBD in the 3 areas of disease interception, remission, and restoration.

During the COVID-19 pandemic, there was a decrease in healthcare utilization among inflammatory bowel disease (IBD) patients at university and safety-net systems. Patients with limited English proficiency, with technology aversion, with financial instability, and who were elderly reported worse perceptions of IBD care during the pandemic.